These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35714942)

  • 1. Synthesis and evaluation of a novel adapter lipid derivative for preparation of cyclic peptide-modified PEGylated liposomes: Application of cyclic RGD peptide.
    Kato N; Sato T; Fuchigami Y; Suga T; Geng L; Tsurumaru M; Hagimori M; Mukai H; Kawakami S
    Eur J Pharm Sci; 2022 Sep; 176():106239. PubMed ID: 35714942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microfluidic Post-Insertion Method for the Efficient Preparation of PEGylated Liposomes Using High Functionality and Quality Lipids.
    Sugimoto Y; Suga T; Kato N; Umino M; Yamayoshi A; Mukai H; Kawakami S
    Int J Nanomedicine; 2022; 17():6675-6686. PubMed ID: 36597433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of High-Functionality and -Quality Lipids with RGD Peptide Ligands: Application for PEGylated Liposomes and Analysis of Intratumoral Distribution in a Murine Colon Cancer Model.
    Suga T; Kato N; Hagimori M; Fuchigami Y; Kuroda N; Kodama Y; Sasaki H; Kawakami S
    Mol Pharm; 2018 Oct; 15(10):4481-4490. PubMed ID: 30179010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulations of cRGD-conjugated PEGylated TiO
    Siani P; Frigerio G; Donadoni E; Di Valentin C
    J Colloid Interface Sci; 2022 Dec; 627():126-141. PubMed ID: 35842963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells.
    Shan D; Li J; Cai P; Prasad P; Liu F; Rauth AM; Wu XY
    Drug Deliv Transl Res; 2015 Feb; 5(1):15-26. PubMed ID: 25787336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
    Yamamoto S; Sakurai Y; Harashima H
    Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery.
    Kibria G; Hatakeyama H; Ohga N; Hida K; Harashima H
    J Control Release; 2011 Jul; 153(2):141-8. PubMed ID: 21447361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.
    Chen CW; Lu DW; Yeh MK; Shiau CY; Chiang CH
    Int J Nanomedicine; 2011; 6():2567-80. PubMed ID: 22128247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and Evaluation of High Functionality and Quality Cell-penetrating Peptide Conjugated Lipid for Octaarginine Modified PEGylated Liposomes In U251 and U87 Glioma Cells.
    El-Gamal FR; Akl MA; Mowafy HA; Mukai H; Kawakami S; Afouna MI
    J Pharm Sci; 2022 Jun; 111(6):1719-1727. PubMed ID: 34863974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temperature-triggered tumor-specific delivery of anticancer agents by cRGD-conjugated thermosensitive liposomes.
    Kim MS; Lee DW; Park K; Park SJ; Choi EJ; Park ES; Kim HR
    Colloids Surf B Biointerfaces; 2014 Apr; 116():17-25. PubMed ID: 24441178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats.
    Chen Z; Deng J; Zhao Y; Tao T
    Int J Nanomedicine; 2012; 7():3803-11. PubMed ID: 22888235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic RGD peptide-modified liposomal drug delivery system for targeted oral apatinib administration: enhanced cellular uptake and improved therapeutic effects.
    Song Z; Lin Y; Zhang X; Feng C; Lu Y; Gao Y; Dong C
    Int J Nanomedicine; 2017; 12():1941-1958. PubMed ID: 28331317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of PEGylation and RGD loading on the targeting properties of radiolabeled liposomal nanoparticles.
    Rangger C; Helbok A; von Guggenberg E; Sosabowski J; Radolf T; Prassl R; Andreae F; Thurner GC; Haubner R; Decristoforo C
    Int J Nanomedicine; 2012; 7():5889-900. PubMed ID: 23226020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125.
    Kim YH; Jeon J; Hong SH; Rhim WK; Lee YS; Youn H; Chung JK; Lee MC; Lee DS; Kang KW; Nam JM
    Small; 2011 Jul; 7(14):2052-60. PubMed ID: 21688390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ligand peptide-grafted PEGylated liposomes using HER2 targeted peptide-lipid derivatives for targeted delivery in breast cancer cells: The effect of serine-glycine repeated peptides as a spacer.
    Suga T; Fuchigami Y; Hagimori M; Kawakami S
    Int J Pharm; 2017 Apr; 521(1-2):361-364. PubMed ID: 28237886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PR_b-targeted PEGylated liposomes for prostate cancer therapy.
    Demirgöz D; Garg A; Kokkoli E
    Langmuir; 2008 Dec; 24(23):13518-24. PubMed ID: 18954096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α₂β₁ receptor.
    Knudsen NØ; Schiffelers RM; Jorgensen L; Hansen J; Frokjaer S; Foged C
    Int J Pharm; 2012 May; 428(1-2):171-7. PubMed ID: 22414425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting tumors with cyclic RGD-conjugated lipid nanoparticles loaded with an IR780 NIR dye: In vitro and in vivo evaluation.
    Choi J; Rustique E; Henry M; Guidetti M; Josserand V; Sancey L; Boutet J; Coll JL
    Int J Pharm; 2017 Nov; 532(2):677-685. PubMed ID: 28279737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.